Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin C studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Vitamin C inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring

Amssayef et al., Cardiovascular & Hematological Disorders-Drug Targets, doi:10.2174/1871529X21666211214153308
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000038 from 71 studies, recognized in 11 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Ex Vivo study showing vitamin C inhibiting vascular ACE2.
Amssayef et al., 14 Dec 2021, peer-reviewed, 3 authors.
Ex Vivo studies are an important part of preclinical research, however results may be very different in vivo.
This PaperVitamin CAll
{ 'DOI': '10.2174/1871529x21666211214153308', 'ISSN': ['1871-529X'], 'URL': 'http://dx.doi.org/10.2174/1871529x21666211214153308', 'abstract': '<jats:sec>\n' '<jats:title>Aims:</jats:title>\n' '<jats:p> The study aimed to assess the inhibitory effect of Vitamin C on ' 'angiotensin-converting enzyme 2.\n' '</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Background:</jats:title>\n' '<jats:p>Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2), which uses angiotensin-converting enzyme 2 (ACE-II)\n' 'as the first route to infect human cells. Accordingly, agents with potential inhibition of ' 'ACE-II receptors might be effective in the prevention and management of COVID-19.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Objective:</jats:title>\n' '<jats:p>The goal of this work was to assess the possible inhibitory effect of ACE-II on ' 'ascorbic\n' 'acid using an ex vivo approach based on the inhibition of diminazene-induced ' 'vasorelaxation.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Material and Methods:</jats:title>\n' '<jats:p>In the present study, diminazene was used as a known specific inhibitor of\n' 'ACE-II. Then, the vasorelaxant effect of ascorbic acid on diminazene-induced relaxation was ' 'examined using isolated aortic rings. All experiments of this study were evaluated on ' 'isolated aortic\n' 'rings precontracted by epinephrine.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Results:</jats:title>\n' '<jats:p>The results confirmed that diminazene-induced vasorelaxation in a dose-dependent ' 'manner. More interestingly, ascorbic acid inhibited diminazene-induced vasorelaxation in a ' 'dose-dependent manner.\n' '</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Conclusion:</jats:title>\n' '<jats:p> This investigation provides valuable experimental proof of the efficacy of ascorbic\n' 'acid (Vitamin C) on inhibiting ex vivo vascular angiotensin-converting enzyme II, which is ' 'known\n' 'among the pharmacological targets of anti-Covid-19 drugs.</jats:p>\n' '</jats:sec>', 'alternative-id': ['LiveAll1'], 'author': [ { 'affiliation': [ { 'name': 'Department of Biology, Team of Ethnopharmacology and ' 'Pharmacognosy, Faculty of Sciences and Techniques, Errachidia, ' 'Moulay Ismail, University of Meknes, BP 509, Boutalamine, 52000 ' 'Errachidia, Morocco'}], 'family': 'Amssayef', 'given': 'Ayoub', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Biology, Team of Ethnopharmacology and ' 'Pharmacognosy, Faculty of Sciences and Techniques, Errachidia, ' 'Moulay Ismail, University of Meknes, BP 509, Boutalamine, 52000 ' 'Errachidia, Morocco'}], 'family': 'Bouadid', 'given': 'Ismail', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biology, Team of Ethnopharmacology and ' 'Pharmacognosy, Faculty of Sciences and Techniques, Errachidia, ' 'Moulay Ismail, University of Meknes, BP 509, Boutalamine, 52000 ' 'Errachidia, Morocco'}], 'family': 'Eddouks', 'given': 'Mohamed', 'sequence': 'additional'}], 'container-title': ['Cardiovascular & Hematological Disorders-Drug Targets'], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2021, 12, 15]], 'date-time': '2021-12-15T06:28:11Z', 'timestamp': 1639549691000}, 'deposited': { 'date-parts': [[2021, 12, 15]], 'date-time': '2021-12-15T06:28:15Z', 'timestamp': 1639549695000}, 'indexed': { 'date-parts': [[2021, 12, 19]], 'date-time': '2021-12-19T11:20:43Z', 'timestamp': 1639912843185}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '1871-529X'}], 'issued': {'date-parts': [[2021, 12, 14]]}, 'language': 'en', 'link': [ { 'URL': 'http://eurekaselect.com/article/download/198905', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/198905/article', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://eurekaselect.com/article/download/198905', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '965', 'original-title': [], 'prefix': '10.2174', 'published': {'date-parts': [[2021, 12, 14]]}, 'published-print': {'date-parts': [[2021, 12, 14]]}, 'publisher': 'Bentham Science Publishers Ltd.', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'score': 1, 'short-container-title': ['CHDDT'], 'short-title': [], 'source': 'Crossref', 'subject': [ 'Cardiology and Cardiovascular Medicine', 'Pharmacology', 'Hematology', 'Molecular Medicine', 'General Medicine'], 'subtitle': [], 'title': ['Vitamin C inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring'], 'type': 'journal-article', 'volume': '21'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit